Express Scripts (ESRX) Guides 2017 EPS In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Express Scripts Holding Company Announces 2017 Financial Guidance
December 14, 2016 7:00 AM ESTST. LOUIS, Dec. 14, 2016 /PRNewswire/ --Â Express Scripts Holding Company (Nasdaq: ESRX) anticipates achieving adjusted earnings per diluted share1 for 2017 in the range of $6.82 to $7.02, representing growth of 7% to 10% from the midpoint of our 2016 adjusted EPS guidance range.Â
"Our value proposition is clear; our opportunities to help patients and payers contain healthcare costs and improve clinical outcomes have never been greater," said Tim Wentworth, CEO and President. "As we continue to evolve our technological capabilities, expand the reach of our pharmacies, and enhance our patient experience, we... More



